Expression of miR-216a in pancreatic cancer and its clinical significance.
- Author:
Baohua HOU
1
;
Zhixiang JIAN
;
Sicong CHEN
;
Yingliang OU
;
Shaojie LI
;
Jinrui OU
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; metabolism; pathology; Adult; Aged; Aged, 80 and over; Female; Humans; Male; MicroRNAs; genetics; metabolism; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; metabolism; pathology
- From: Journal of Southern Medical University 2012;32(11):1628-1631
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the clinical significance of miRNA-216a expression in pancreatic cancer.
METHODSFourteen patients with pancreatic cancer undergoing pancreaticoduodenectomy and 6 patients with benign pancreas lesions were examined for miR-216a expressions in the tumor or lesion tissues using Agilent Human miRNA Microarray (V12.0). The relationship between miR-216a expressions and the clinicopathological features of the patients was analyzed.
RESULTSThe expression of miRNA-216a was significantly lower in pancreatic cancer than in benign pancreas lesions (P=0.000). The expression of miRNA-216a was significantly correlated with the T stage of the tumor (P=0.002), but not with the patients' age, gender, smoking status, tumor stage, lymph node metastases, distant metastasis, tumor differentiation, nerve invasion, vessel invasion or serum CA19-9 level (P>0.05).
CONCLUSIONSThe down-regulated expression of miR-216a in pancreatic cancer suggests the involvement of miR-216a in the tumorigenesis and development of pancreatic cancer. miR-216a may potentially serve as a novel tumor marker and also a prognostic factor for pancreatic cancer.
